1 / 8

Study Design

Study Design. 1 21 Relapsing-remitting MS patients randomized to Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24 weeks Additional 24 weeks of follow-up Wait-list control* MS treatment as usual for 10+ months 5-hour workshop after 10th month

yuma
Download Presentation

Study Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Study Design • 121 Relapsing-remitting MS patients randomized to • Stress Management Therapy MS active treatment* • 16 individual sessions conducted over24 weeks • Additional 24 weeks of follow-up • Wait-list control* • MS treatment as usual for 10+ months • 5-hour workshop after 10th month • MRIs performed at weeks 8,16,24,32,40, & 48 *All patients continued their usual disease-modifying therapy. Mohr DC, et al. Neurology. 2012;79:412-419.

  2. Study Design • Primary endpoint • Cumulative number of new Gd+ lesions at weeks 8, 16, and 24 • Secondary endpoints • Cumulative number of new/enlarging T2 lesions • Patients free of new Gd+ and new T2 lesions • T2 volume change • Brain volume change • Stress • Clinical exacerbation Mohr DC, et al. Neurology.2012;79:412-419.

  3. Reduction in Cumulative Gd+ Lesions and New T2 Lesions (24 Weeks) SMT-MS Group Control Group (n = 61) (n = 60) P Value Cumulative Gd+ lesions Number 50th percentile 0 0 75th percentile 0 1 .04 Patients free from Gd+ lesions 76.8% 54.7% .02 Absolute risk reduction: 22.2% New T2 lesions Number 50th percentile 0 1 75th percentile 1 3 .005 Patients free from new lesions 69.5% 42.7% .006 Absolute risk reduction: 26.8% Abbreviation: SMT-MS, stress management therapy – multiple sclerosis.Mohr DC, et al. Neurology. 2012;79:412-419.

  4. Changes in Brain Volume*and Stress† SMT-MS Group Control Group (n = 61) (n = 60) P Value Brain volume % change -0.11 -0.43 .01 Stress Life Events Scale Baseline 3.1 ± 2.3 2.9 ± 2.3 Week 24 1.5 ± 1.2 1.8 ± 1.2 .04 Brief Inventory of Perceived Stress Baseline 18.2 ± 5.7 17.3 ± 6.3 Week 24 16.3 ± 6.2 17.5 ± 6.2 .007 *Assessed at 48 weeks; †Assessed at 24 weeks. Mohr DC, et al. Neurology. 2012;79:412-419.

  5. Clinical Outcomes • No significant differences between groups in confirmed exacerbations • Baseline to week 24 • 22 in Stress Management Therapy-MS (SMT-MS) group vs 22 in control group (P = .84) • Week 24−48 • 15 in SMT-MS group vs 18 in control group (P = .40) • No significant differences between groups in Expanded Disability Status Scale over the trial period (P = .15) Mohr DC, et al. Neurology. 2012;79:412-419.

  6. Follow-Up at 48 Weeks No statistically significant differences remained between groups in terms of • Cumulative number of Gd+ lesions • Cumulative number of new or enlarging T2 lesions • Patients remaining free of Gd+ lesions • Patients remaining free of new T2 lesions • Levels of stress Mohr DC, et al. Neurology. 2012;79:412-419.

  7. Possible Reasons Why Benefits Were Not Maintained • Patients were able to employ the new coping skills as long as they were receiving treatment, but were unable to continue these behavioral changes without ongoing program support • Expectations on the part of patients and/or the supportive relationship provided by treatment may have accounted for the benefits of the SMT-MS intervention Mohr DC, et al. Neurology. 2012;79:412-419.

  8. Conclusions • Stress management therapy: Effective in reducing new Gd+ lesions and new/enlarging T2 lesions, even in patients with higher disease activity • Findings provide firm evidence of the link between stress and increased MRI activity • Ongoing stress management therapy may be necessary to sustain the benefit of treatment

More Related